Events Pharmaceuticals

Pharmaceuticals

DCAT After The Show 2026

Mid-size
📅 9 October 2026 📍 TBD, Milan, IT ↗ 🏢 Drug, Chemical & Associated Technologies Association (DCAT) 🔁 Annual

DCAT After The Show is an informal networking event organized by the Drug, Chemical & Associated Technologies Association (DCAT). Held immediately following the trade show floor in Milan, the event allows attendees to unwind over refreshments and hors d'oeuvres. It features no formal agenda or presentations, focusing entirely on relationship-building and networking.

Attendees: DCAT Member Company representatives, including executives and decision-makers from the global bio/pharmaceutical industry.

NetworkingBusiness DevelopmentBio/Pharmaceuticals networkingbio/pharmaceuticalbusiness developmentDCAT

Filter this event to your ICP.

Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.

Request intelligence →

Delivery within 24 hours · $1,250

⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.

Organizer

Drug, Chemical & Associated Technologies Association, Inc. (DCAT)

Nonprofit · Robbinsville, United States · Founded 1890

A non-profit professional association for companies in the pharmaceutical, chemical, and related industries.

Runs 3 events → Full portfolio ↗

Why people attend

Buyers and industry professionals attend to network with key decision-makers and establish partnerships in a relaxed, post-show environment.

Sample matches

Filtered to a Series-B SaaS ICP. Your filter will be different.

Sample Match A

example.com

91 — High
Enterprise SaaS200–500 employeesAmsterdam, NL

"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."

Sample Match B

example.io

79 — Medium
Cloud platform50–200 employeesLondon, UK

"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."

████████ ██████

████████.io

██ — Medium
████████████ 200–500 employees ████, ██

"████████████████████████████████████████."

Submit your ICP
to unlock all matches

Request intelligence →

████████ ██████

████████.io

██ — Medium
████████████ 200–500 employees ████, ██

"████████████████████████████████████████."

Submit your ICP
to unlock all matches

Request intelligence →

Speakers

28 speakers at DCAT After The Show

D

Dr. Christine Allen

CEO & Co-founder, Professor · Intrepid Labs Inc., University of Toronto

"SHAPING THE FUTURE: DIGITAL TOOLS FOR DURABLE TRANSFORMATION IN BIO/PHARMA – KEYNOTE"

Bio

In this keynote, Dr. Christine Allen will share a practical vision for the future of bio/pharma: a digital-by-design approach to drug development where experiments, decisions, and supply chains are connected through a modern data backbone. She will explore how AI, high-throughput automation, and cloud-native infrastructure can expand the formulation and process design space while addressing what matters from the start, including patient experience, manufacturability, cost-per-dose, and supplier resilience across regions. Drawing on lessons from integrating AI into established development workflows, she will highlight what makes digital transformation durable: tools designed with domain experts, transparent trade-offs, and human-in-the-loop decision support that strengthens scientific judgment. The talk will also touch on how these approaches can identify critical issues earlier and strengthen the path from development to commercialization.

digital transformationAI in drug developmentsupply chain resilience
T

Thomas Altmann

Executive Vice President, Innovation & New Technology · Acwa Power

"DIGITAL TRANSFORMATION THAT DELIVERS: HOW PHARMA LEADERS ARE BUILDING SMARTER, FASTER & MORE RESILIENT INTERNAL PROCESSES"

Bio

Thomas Altmann is the Executive Vice President for Innovation and New Technology at ACWA Power, where he has led transformative initiatives in clean energy and desalination for over 13 years. With more than three decades of global experience, Thomas is recognized as a leading expert in deploying breakthrough technologies that accelerate sustainable infrastructure. Previously, he held senior leadership roles at ILF Consulting Engineers and Bechtel, overseeing large-scale energy and desalination projects across international markets. At ACWA Power, he established the company’s Innovation Department, launched its flagship Innovation Days, and drove key achievements including up to 80% reductions in desalination energy use, deployment of AI/ML in plant operations, creation of a 30-patent IP portfolio, and formation of ACWA Power’s IP Holding Company. Thomas serves on global innovation and R&D boards, including the International Desalination Association, MIT Technology Review Global Panel, and XPrize Desalination Competition. He holds a Master’s in Chemical Engineering and advanced innovation credentials from MIT Sloan and IMD.

clean energydesalinationcorporate-startup collaboration

Also speaking at Innovation Zero

C

Clemente Aguila

Head of Operations & Corporate Procurement · Grifols

"DIGITAL TRANSFORMATION THAT DELIVERS: HOW PHARMA LEADERS ARE BUILDING SMARTER, FASTER & MORE RESILIENT INTERNAL PROCESSES"

digital transformationprocurementsupply chain
K

Ken Seufert

Chief Executive Officer · JRS Pharma, LP

"DIGITAL TRANSFORMATION THAT DELIVERS: HOW PHARMA LEADERS ARE BUILDING SMARTER, FASTER & MORE RESILIENT INTERNAL PROCESSES"

digital transformationpharma leadershipsupply chain
S

Steffen Denzinger

President, Board of Directors · European Fine Chemicals Group

"THE CRITICAL MEDICINES ACT – PERSPECTIVES FROM EUROPE’S CDMO AND EXCIPIENTS INDUSTRY"

Critical Medicines Actpharma supply chainEuropean manufacturing
R

Roman Lagoutte

Senior Principal Scientist · Lonza

"AI-DRIVEN DRUG DEVELOPMENT: ACCELERATING API PROCESS STAGES, FROM ROUTE SCOUTING TO MANUFACTURING"

AI in drug developmentAPI manufacturingprocess design
A

Anil Kane

Global Head of Technical & Scientific Affairs Pharma Services · Thermo Fisher Scientific

"AI-DRIVEN DRUG DEVELOPMENT: ACCELERATING API PROCESS STAGES, FROM ROUTE SCOUTING TO MANUFACTURING"

AI in drug developmentAPI manufacturingprocess design
M

Michael Semo

Associate Vice President · Eli Lilly and Company

"AI-DRIVEN DRUG DEVELOPMENT: ACCELERATING API PROCESS STAGES, FROM ROUTE SCOUTING TO MANUFACTURING"

AI in drug developmentAPI manufacturingprocess design
A

Andrew Lewis

Executive General Manager, Consumer, Markets and Analytics · AEMC

"CASE STUDIES: TECHNOLOGY IN ACTION"

Bio

Andrew joined the Australian Energy Market Commission (AEMC) in February 2024 from the NSW Government. He has extensive senior leadership, stakeholder engagement, communication and management experience from a mix of industry and government executive roles. At the AEMC, Andrew is responsible for leading the strategic direction and delivery of comprehensive market design Reviews and Rule Changes to provide policy recommendations that inform decision-making and support the achievement of strategic objectives to deliver for the long-term interest of energy consumers. Focusing mostly on the wholesale and retail components of the energy sector, Andrew’s current work priorities include projects on Consumer Energy Resources, consumer protection frameworks, future wholesale market design and supporting reliability. Andrew brings proven success in regulatory, program and policy development, implementation and advocacy; building, leading and motivating teams; and identifying strategic directions, implementing change and delivering customer-focused outcomes and reforms. Andrew has over 20 years’ experience working in and around energy in a variety of roles, and brings perspectives from his time at government agencies, an energy peak body, energy market participants and ministerial offices. He has held senior executive positions with a strong focus on developing and implementing strategies and programs for energy market reforms, policy and regulatory analysis and development, consumer protection and support, stakeholder engagement and technical regulation.

consumer participationenergy transitionconsumer protection

Also speaking at The Fire Safety Event

Y

Yaman Tobaje

Senior Engineer, MSAT · Made Scientific

"CASE STUDIES: TECHNOLOGY IN ACTION"

technology case studiespharma innovation
Y

Yu-Shun (Leo) Hsiao

Founder & CEO · Streamline Bio

"CASE STUDIES: TECHNOLOGY IN ACTION"

technology case studiespharma innovation
T

Timo Liebig

Chief Innovation Officer · Mabxience

"CASE STUDIES: TECHNOLOGY IN ACTION"

technology case studiespharma innovation
F

Félix Fernández Romero

Director of AI Transformation and Business Development · HP

"CASE STUDIES: TECHNOLOGY IN ACTION"

technology case studiespharma innovation
M

Michael Schorpp

Head of Digital Innovation & AI, Global Regulatory Affairs · Boehringer Ingelheim

"TRUST BY DESIGN: APPLYING QUALITY BY DESIGN PRINCIPLES TO TRUSTWORTHY AI"

trustworthy AIQuality by Designregulatory AI
G

Graham Lewis

Chief Officer University Environments and Property · Estates 360

"EUROPEAN PHARMA MARKET INTELLIGENCE & FINANCIAL OUTLOOK"

Bio

Graham, Managing Director at Estates 360, brings over two decades of experience delivering estate-related programmes, in both client and consultancy capacities. Specialising in complex organisational programmes, he has led masterplanning, capital project and estate management teams. His educational portfolio includes schools and HE institutions, and ranges from 20 year masterplans to research supercomputing facilities, and from listed building conversions to on-campus transport infrastructure. Beyond educational estates, Graham draws on his experience in operational and delivery roles leading schemes across diverse sectors including local government, healthcare, heritage, infrastructure, retail, commercial, and aviation. Graham's previous roles include Head of Construction, Maintenance, and FM at a local authority, and as Head of a Regional Project Management team at an international consultancy. His focus is on assisting clients in navigating the competing challenges of ageing infrastructure, diminishing funding, net zero commitments, and the impacts of the fourth industrial revolution.

Also speaking at Education Estates Conference and Exhibition, DCAT Week

G

Gijs Vissers

Head of Supply and Procurement · Nordic Pharma

"BUILDING A RESILIENT PHARMA SUPPLY CHAIN: STRATEGY, RISK & INNOVATION FOR THE FUTURE"

supply chain resiliencerisk managementpharma procurement

+ 12 more speakers at this event.

More Pharmaceuticals events

Pharmaceuticals

APhA2027 Annual Meeting & Exposition

Phoenix, US Mar 2027

Pharmaceuticals

ASAP BioPharma Conference

Boston, US Nov 2027

Pharmaceuticals

IFPW General Membership Meeting (GMM)

Mexico City, MX Oct 2026

Pharmaceuticals

IFPW CEO Roundtable

London, GB Apr 2027

More Pharmaceuticals events

All Pharmaceuticals trade showsAll events in Italy

Frequently asked questions

When is DCAT After The Show?+
DCAT After The Show takes place on 9 October 2026.
Where is DCAT After The Show held?+
DCAT After The Show is held at TBD, Milan, IT.
Who organises DCAT After The Show?+
DCAT After The Show is organised by Drug, Chemical & Associated Technologies Association (DCAT).
How often is DCAT After The Show held?+
DCAT After The Show is held annual.

Ready to map DCAT After The Show?

Request intelligence →